OncoSignal
Live from Open Targets Platform, fetched 2026-11-11 15:11 UTC. Every row links to its source record.

DICER1 dicer 1, ribonuclease III

ENSG00000100697 · protein coding · Open Targets profile

Double-stranded RNA (dsRNA) endoribonuclease playing a central role in short dsRNA-mediated post-transcriptional gene silencing. Cleaves naturally occurring long dsRNAs and short hairpin pre-microRNAs (miRNA) into fragments of twenty-one to twenty-three nucleotides with 3' overhang of two nucleotides, producing respectively short interfering RNAs (siRNA) and mature microRNAs. SiRNAs and miRNAs serve as guide to direct the RNA-induced silencing complex (RISC) to complementary RNAs to degrade them or prevent their translation. Gene silencing mediated by siRNAs, also called RNA interference, controls the elimination of transcripts from mobile and repetitive DNA elements of the genome but also the degradation of exogenous RNA of viral origin for instance. The miRNA pathway on the other side is a mean to specifically regulate the expression of target genes. {ECO:0000269|PubMed:15242644, ECO:0000269|PubMed:15973356, ECO:0000269|PubMed:16142218, ECO:0000269|PubMed:16271387, ECO:0000269|PubMed:16289642, ECO:0000269|PubMed:16357216, ECO:0000269|PubMed:16424907, ECO:0000269|PubMed:17452327, ECO:0000269|PubMed:18178619}.

In 8 of 15 cancers, the evidence for DICER1 comes mainly from inherited variants

Each row is a cancer, strongest overall evidence first. The two dots show how strong the inherited (germline) and tumour-mutation (somatic) evidence is; the line between them is the gap.

Inherited (germline) variantsMutations in tumours (somatic)
00.250.50.751pleuropulmonary blastomapleuropulmonary blastomapleuropulmonary blastoma: germline 0.86goiter, multinodular 1, with or without…goiter, multinodular 1, with or without Sertoli-Leydig cell tumorsgoiter, multinodular 1, with or without Sertoli-Leydig cell tumors: germline 0.84global developmental delay - lung cysts…global developmental delay - lung cysts - overgrowth - Wilms tumor syndromeglobal developmental delay - lung cysts - overgrowth - Wilms tumor syndrome: germline 0.85rhabdomyosarcoma, embryonal, 2rhabdomyosarcoma, embryonal, 2rhabdomyosarcoma, embryonal, 2: germline 0.89embryonal rhabdomyosarcomaembryonal rhabdomyosarcomaembryonal rhabdomyosarcoma: somatic 0.61pineoblastomapineoblastomapineoblastoma: somatic 0.46pineoblastoma: germline 0.83hereditary neoplastic syndromehereditary neoplastic syndromehereditary neoplastic syndrome: germline 0.94rhabdomyosarcomarhabdomyosarcomarhabdomyosarcoma: germline 0.68melanomamelanomamelanoma: somatic 0.54colorectal adenocarcinomacolorectal adenocarcinomacolorectal adenocarcinoma: somatic 0.53ovarian cancerovarian cancerovarian cancer: germline 0.62sarcomasarcomasarcoma: somatic 0.61Cystic NephromaCystic NephromaCystic Nephroma: somatic 0.61cutaneous melanomacutaneous melanomacutaneous melanoma: somatic 0.61skin basal cell carcinomaskin basal cell carcinomaskin basal cell carcinoma: somatic 0.61

Scores run from 0 (no evidence) to 1 (strongest). A missing dot at 0 means Open Targets holds no evidence of that kind. Source: Open Targets Platform, fetched live.

Tractability

PROTAC
Database Ubiquitination, Half-life Data

gnomAD loss of function constraint: o/e 0.22148999571800232 (upper bound 0.28560999035835266). Low values mean loss of function is poorly tolerated, a safety flag for inhibition.

Who runs trials of these drugs

No named investigators on registry trials of DICER1's approved or late-stage drugs in the last three years.

No terminated, withdrawn or suspended trials of DICER1's drugs are registered

All 0 drugs and clinical candidates as a table

Each drug, stage and indication links to its Open Targets record, where the trials and approvals behind it are listed. Salt forms (for example a mesylate) are listed as Open Targets records them, as separate entries.

DrugTypeHighest stageIndicationsSource records
No drugs or clinical candidates recorded.